Abstract 83P
Background
Pancreatic cancer is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. The dismal prognosis is primarily due to late-stage diagnosis, resulting from the absence of specific, early, and sensitive biomarkers. Macrophage inhibitory cytokine 1 (MIC-1), a member of the transforming growth factor-beta superfamily, has been proposed as a potential biomarker for the early diagnosis of pancreatic cancer. However, the existing literature reports inconsistent diagnostic performance for serum MIC-1 levels in pancreatic cancer detection. This study aims to evaluate the diagnostic accuracy of serum MIC-1 as a biomarker for pancreatic cancer.
Methods
A systematic review was performed in PubMed, Embase, Web of Science, and Scopus to identify relevant studies published up to January 2023. These studies assessed assessing usage of MIC-1 in pancreatic cancer patients, with healthy individuals serving as the comparator control group. Statistical analysis was performed using R software (version 4.0.3) with the mada package to pool sensitivity, specificity, false-positive rate estimates, diagnostic odds ratio, and positive and negative likelihood ratios; each expressed within a 95% Confidence Interval (CI).
Results
Analysis of five studies involving 2008 participants (1151 pancreatic cancer patients, 857 healthy controls) revealed a robust diagnostic performance for serum MIC-1 levels, with a high pooled sensitivity of 86.7% (95% CI, 75.4-93.3%, I2=93.9%) and specificity of 85.9% (95% CI, 66.9-94.9%, I2=94%). A false-positive rate of 14.1% (95% CI, 5.1-33.1%) was noted. Positive and negative likelihood ratios were 6.17 (95% CI, 2.37-16.05) and 0.15 (95% CI, 0.08-0.30), respectively, and a high diagnostic odds ratio of 39.92 (95% CI, 10.44-152.66) indicated strong efficacy for MIC-1 as a diagnostic biomarker.
Conclusions
Serum MIC-1 demonstrates substantial potential as an early diagnostic biomarker for pancreatic cancer due to its high sensitivity and specificity. Nevertheless, the significant heterogeneity in the studies calls for more extensive, well-designed prospective validation studies before clinical implementation.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract